A wide range screening of normal human tissues by immunohistochemistry revealed no expression of BCMA except in lymphoid tissue, suggesting that an anti-BCMA CAR T-cell therapy will have favorable efficacy in MM [57]. Here, TNFRSF17 is linked to Miyoshi myopathy.